المؤلفون: Andi Ade Wijaya Ramlan, Dimas K. Bonardo Pardede, Arif H. M. S Marsaban, Jefferson Hidayat, Fildza Sasri Peddyandhari

المصدر: Journal of Anaesthesiology Clinical Pharmacology, Vol 36, Iss 2, Pp 177-181 (2020)

مصطلحات موضوعية: agitation, children, delirium, emergence, propofol, sevoflurane, Anesthesiology, RD78.3-87.3, Pharmacy and materia medica, RS1-441

الوصف: Background and Aims: Emergence agitation (EA) is a common transient behavioral disturbance after inhalational anesthesia and may cause harm to the patient. This study evaluated the efficacy of 0.5 mg/kg of propofol administered at the end of anesthesia to reduce the incidence of EA in children undergoing general inhalational anesthesia. Material and Methods: This double-blind randomized clinical trial was done in children aged 1–5 years undergoing general anesthesia with sevoflurane. One hundred and eight subjects were included using consecutive sampling method and randomized into two equal groups. Propofol in the dose of 0.5 mg/kg was administered at the end of anesthesia to children in the propofol group, while those in the control group did not receive any intervention at the end of anesthesia. Incidence of EA, transfer time, postoperative hypotension, desaturation, and nausea-vomiting were observed. Aono and Pediatric Anesthesia Emergence Delirium scale were used to assess EA. Results: Incidence of EA was 25.9% in the propofol group compared to 51.9% in the control group (RR = 0.500; 95% CI 0.298–0.840; P = 0.006). Mean transfer time in propofol group was longer (9.5 ± 3.9 min) than control group (7.8 ± 3.6 min) (mean difference 1.71 min; 95% CI 0.28–3.14; P = 0.020). Hypotension was found in one patient (1.9%) in propofol group, while in control group there was none. Nausea-vomiting was found in five patients (9.3%) in propofol group and eight patients (14.8%) in control. There was no desaturation in both the groups. Conclusion: Administration of 0.5 mg/kg of propofol at the end of anesthesia effectively reduces the incidence of EA in children undergoing general inhalational anesthesia with sevoflurane.

وصف الملف: electronic resource

العلاقة: http://www.joacp.org/article.asp?issn=0970-9185;year=2020;volume=36;issue=2;spage=177;epage=181;aulast=RamlanTest; https://doaj.org/toc/0970-9185Test

الوصول الحر: https://doaj.org/article/43d40cd6576e436c8301897489c9c366Test

المؤلفون: Sudung O. Pardede, Dimas K. Bonardo

المصدر: Sari Pediatri, Vol 13, Iss 4, Pp 285-92 (2016)

مصطلحات موضوعية: rituximab, sindrom nefrotik dependen steroid, sindrom nefrotik resisten steroid, Medicine, Pediatrics, RJ1-570

الوصف: Sebagian besar pasien sindrom nefrotik memberikan respons yang baik dengan steroid, tetapi terdapat pasien yang tidak responsif dengan steroid dan sulit mengalami remisi, disebut sindrom nefrotik refrakter. Berbagai regimen obat telah diberikan untuk menghindari atau mengurangi efek samping steroid, seperti siklofosfamid, klorambusil, siklosporin, vinkristin, mikofenolat mofetil, dan takrolimus dengan hasil yang bervariasi dan berbagai efek samping. Rituximab adalah antibodi monoklonal anti-CD20 yang menginduksi aktivitas imunologis yang dimediasi oleh komplemen dan mencetuskan aktivitas selular tergantung antibodi (antibody-dependent). Rituximab telah diberikan untuk mengobati sindrom nefrotik refrakter, dan pada sindrom nefrotik relaps sering, terjadi remisi dan tidak timbul relaps. Penelitian multisenter untuk sindrom nefrotik dependen steroid dan resisten steroid, memperlihatkan terjadi remisi pada sebagian besar pasien. Pemberian rituximab pada sindrom nefrotik dengan gambaran patologi anatomi kelainan minimal, nefropati membranosa, dan glomerulosklerosis fokal segmental menyebabkan remisi pada sebagian besar pasien. Keberhasilan rituximab dalam tata laksana sindrom nefrotik idiopatik merupakan bukti terdapatnya peran limfosit B dalam patogenesis sindrom nefrotik. Dosis yang sering digunakan 375 mg/m 2 LPB secara intravena diberikan 4 dosis dengan interval satu minggu atau dosis 750 mg/m 2 LPB diberikan dua dosis selang waktu dua minggu. Rituximab dapat mengurangi aktivitas penyakit dan memperbaiki sensitivitas terhadap obat imunsupresan. Efek samping yang sering terjadi berupa reaksi akut seperti demam, nyeri abdomen, diare, muntah, ruam kulit, bronkospasme, takikadia, dan hipertensi. Rituximab memberikan hasil yang baik dalam tata laksana sindrom nefrotik refrakter, namun diperlukan uji klinik dengan jumlah sampel yang cukup untuk menilai efikasi dan keamanan obat

وصف الملف: electronic resource

العلاقة: https://saripediatri.org/index.php/sari-pediatri/article/view/443Test; https://doaj.org/toc/0854-7823Test; https://doaj.org/toc/2338-5030Test

الوصول الحر: https://doaj.org/article/851ed20b561049e9ae8ce70f43097e3bTest

المؤلفون: Magouliotis, D., Dimas, K., Sakellaridis, N., Ioannou, M., Zacharouli, K., Ntalagiorgos, A., Fergadi, M., Zacharoulis, D.

المصدر: HPB ; volume 24, page S304 ; ISSN 1365-182X

مصطلحات موضوعية: Gastroenterology, Hepatology

الإتاحة: https://doi.org/10.1016/j.hpb.2022.05.642Test
https://api.elsevier.com/content/article/PII:S1365182X22007778?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S1365182X22007778?httpAccept=text/plainTest

المؤلفون: Magouliotis, D., Fergadi, M., Sakellaridis, N., Dimas, K., Tatsios, E., Zacharoulis, D.

المصدر: HPB ; volume 23, page S886 ; ISSN 1365-182X

مصطلحات موضوعية: Gastroenterology, Hepatology

الإتاحة: https://doi.org/10.1016/j.hpb.2021.08.828Test
https://api.elsevier.com/content/article/PII:S1365182X21014726?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S1365182X21014726?httpAccept=text/plainTest

المؤلفون: Magouliotis, D., Dimas, K., Sakellaridis, N., Fergadi, M., Symeonidis, D., Zacharoulis, D.

المصدر: HPB ; volume 23, page S242 ; ISSN 1365-182X

مصطلحات موضوعية: Gastroenterology, Hepatology

الإتاحة: https://doi.org/10.1016/j.hpb.2020.11.608Test
https://api.elsevier.com/content/article/PII:S1365182X20318529?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S1365182X20318529?httpAccept=text/plainTest

المؤلفون: Kamposioras, Konstantinos, Dinas, P. C., Barriuso, Jorge, Trachana, V., Dimas, K.

المساهمون: The Christie NHS Foundation Trust, Manchester, UK

الوصف: Background: Gastrointestinal (GI) cancers remain a major threat worldwide, accounting for over 30% of cancer deaths. The identification of novel prognostic biomarkers remains a challenge despite significant advances in the field. The CAV1 gene, encoding the caveolin-1 protein, remains enigmatic in cancer and carcinogenesis, as it has been proposed to act as both a tumour promoter and a tumour suppressor. Methods: To analyse the differential role of caveolin-1 expression in both tumour cells and stroma in relation to prognosis in GI tumours, we performed a systematic review and meta-analysis according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines; PROSPERO registration number: CRD42022299148. Results: Our analysis showed that high levels of caveolin-1 in tumour cells were associated with poor prognosis and inferior overall survival (OS) in oesophageal and pancreatic cancer and hepatocellular carcinoma (HCC), but not in gastric and colorectal cancer. Importantly, our study showed that higher stromal caveolin-1 expression was associated with significantly longer OS and disease-free survival in colorectal cancer. Analysis of stromal caveolin-1 expression in the remaining tumours showed a similar trend, although it did not reach statistical significance. Conclusions: The data suggest that caveolin-1 expression in the tumour cells of oesophageal, pancreatic cancer and HCC and in the stroma of colorectal cancer may be an important novel predictive biomarker for the clinical management of these diseases in a curative setting. However, the main conclusion of our analysis is that caveolin-1 expression should always be assessed separately in stroma and tumour cells.

العلاقة: https://dx.doi.org/10.1111/eci.14065Test; Kamposioras K, Dinas PC, Barriuoso J, Trachana V, Dimas K. Caveolin-1 protein expression as a prognostic biomarker of gastrointestinal tumours: A systematic review and meta-analysis. Eur J Clin Invest. 2023 Jul 27:e14065. PubMed PMID: 37497737. Epub 2023/07/27. eng.; http://hdl.handle.net/10541/626479Test; European Journal of Clinical Investigation

الإتاحة: https://doi.org/10.1111/eci.14065Test
http://hdl.handle.net/10541/626479Test

المؤلفون: Kamposioras, K, Tsimplouli, C, Verbeke, C, Anthoney, A, Daoukopoulou, A, Papandreou, CN, Sakellaridis, N, Vassilopoulos, G, Potamianos, SP, Liakouli, V, Migneco, G, Del Galdo, F, Dimas, K

الوصف: Caveolin‑1 (Cav‑1) expression has been shown to be associated with tumor growth and resistance to chemotherapy in pancreatic cancer. The primary aim of this study was to explore the significance of Cav‑1 expression in pancreatic cancer cells as compared to fibroblasts in relation to cancer cell proliferation and chemoresistance, both in vitro and in vivo, in an immunodeficient mouse model. We also aimed to evaluate the immunohistochemical expression of Cav‑1 in the epithelial and stromal component of pancreatic cancer tissue specimens. The immunohistochemical staining of poorly differentiated tissue sections revealed a strong and weak Cav‑1 expression in the epithelial tumor cells and stromal fibroblasts, respectively. Conversely, the well‑differentiated areas were characterized by a weak epithelial Cav‑1 expression. Cav‑1 downregulation in cancer cells resulted in an increased proliferation in vitro; however, it had no effect on chemoresistance and growth gain in vivo. By contrast, the decreased expression of Cav‑1 in fibroblasts resulted in a growth advantage and the chemoresistance of cancer cells when they were co‑injected into immunodeficient mice to develop mixed fibroblast/cancer cell xenografts. On the whole, the findings of this study suggest that the downregulation of Cav‑1 in fibroblasts is associated with an increased tumor proliferation rate in vivo and chemoresistance. Further studies are warranted to explore whether the targeting of Cav‑1 in the stroma may represent a novel therapeutic approach in pancreatic cancer.

وصف الملف: text

العلاقة: https://eprints.whiterose.ac.uk/156970/1/ijo_54_2_537_PDF.pdfTest; Kamposioras, K, Tsimplouli, C, Verbeke, C et al. (10 more authors) (2019) Silencing of caveolin-1 in fibroblasts as opposed to epithelial tumor cells results in increased tumor growth rate and chemoresistance in a human pancreatic cancer model. International Journal of Oncology, 54 (2). pp. 537-549. ISSN 1019-6439

الإتاحة: https://eprints.whiterose.ac.uk/156970Test/
https://eprints.whiterose.ac.uk/156970/1/ijo_54_2_537_PDF.pdfTest

المؤلفون: Sereti, E., Tsimplouli, C., Cevatemre, B., Ulukaya, E., Sakellaridis, N., Dimas, K.

المصدر: ESMO Open ; volume 3, page A310 ; ISSN 2059-7029

مصطلحات موضوعية: Cancer Research, Oncology

الإتاحة: https://doi.org/10.1136/esmoopen-2018-eacr25.731Test
https://api.elsevier.com/content/article/PII:S2059702920317804?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S2059702920317804?httpAccept=text/plainTest

المؤلفون: Magouliotis, D., Tasiopoulou, V., Dimas, K., Sakellaridis, N., Zacharoulis, D.

المصدر: HPB ; volume 20, page S564 ; ISSN 1365-182X

مصطلحات موضوعية: Gastroenterology, Hepatology

الإتاحة: https://doi.org/10.1016/j.hpb.2018.06.2033Test
https://api.elsevier.com/content/article/PII:S1365182X18334130?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S1365182X18334130?httpAccept=text/plainTest

المؤلفون: Magouliotis, D., Tasiopoulou, V., Dimas, K., Sakellaridis, N., Zacharoulis, D.

المصدر: HPB ; volume 20, page S323-S324 ; ISSN 1365-182X

مصطلحات موضوعية: Gastroenterology, Hepatology

الإتاحة: https://doi.org/10.1016/j.hpb.2018.06.355Test
https://api.elsevier.com/content/article/PII:S1365182X1831205X?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S1365182X1831205X?httpAccept=text/plainTest